Author(s): Melnik I, Lotem M, Yoffe B
Abstract Share this page
Abstract Vemurafenib is approved by the FDA for the management of unresectable or metastatic melanoma. However, its role as a neoadjuvant therapy has not been determined. We present the first documented case in which vemurafenib induced complete tumor necrosis of both lymph node and brain metastases within one month or less, an outcome that indicated that the patient was a good candidate for excisional surgery.
This article was published in Case Rep Oncol Med
and referenced in Journal of Cytology & Histology